ADCT vs NCLH · rev $40.1M vs P/E 16, rev $4.97B
ADC Therapeutics SA (ADCT) versus Norwegian Cruise Line Holdings Ltd (NCLH) — a side-by-side from cached financials, not a winner call.
ADC Therapeutics SA (ADCT) is a biotechnology company listed on NYSE.
Norwegian Cruise Line Holdings Ltd (NCLH) is a travel services company listed on NYSE.
Latest reported ADCT revenue for 2026-06-30 was $40.1M. Net income was -$49.5M. Revenue was up 92.3% from 2026-03-31 to 2026-06-30. ADCT currently screens at market cap $141.2M.
Latest reported NCLH revenue for 2026-06-30 was $4.97B. Net income was $327.2M. NCLH currently screens at market cap $9.10B and trailing P/E 16.0.
ADCT currently screens at market cap $141.2M. NCLH currently screens at market cap $9.10B and trailing P/E 16.0.
Not investment advice. Open the ADCT and NCLH stock pages for the full models.
Not investment advice.